STOCK TITAN

TVTX Form 144 Filed for 10,000 Shares via Morgan Stanley — $250K

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 notice for Travere Therapeutics, Inc. (TVTX) reports a proposed sale of 10,000 common shares through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $250,000.00. The filing states the shares were acquired and will be sold on 09/22/2025 via a stock option exercise from the issuer, with payment in cash. The issuer's outstanding shares are listed as 89,138,673. The filer reports no securities sold in the past three months. Several identifying fields (filer CIK and contact details) are blank in the provided text.

Positive

  • Transaction is fully documented with acquisition date, sale date, broker, payment method, and aggregate value provided
  • No securities sold in prior three months, as explicitly reported

Negative

  • Filer identification fields are incomplete or blank in the provided text (CIK and contact details missing), limiting verification from this extract

Insights

TL;DR: Routine Rule 144 notice for disposition of option-exercised shares; documentation shows cash payment and brokered sale.

The filing documents a proposed sale under Rule 144 of 10,000 common shares acquired by stock option exercise and intended for sale the same day through Morgan Stanley Smith Barney LLC on NASDAQ. The filing includes the aggregate market value and the issuer's total outstanding shares, and it states there were no sales in the prior three months. Some filer identification fields in the supplied extract are blank, which limits verification from this text alone.

TL;DR: Small, clearly identified sale; no recent disposals reported and proceeds will be cash-settled through a broker.

The notice indicates a single proposed disposition of 10,000 shares valued at $250,000, acquired and to be sold on 09/22/2025 via stock option exercise with cash payment. The statement that nothing was sold in the prior three months is included. From an equity perspective within this filing, the detail is transactional and does not present operational or financial results.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Travere Therapeutics' (TVTX) Form 144 report?

The Form 144 reports a proposed sale of 10,000 common shares valued at $250,000, to be sold on 09/22/2025 on NASDAQ through Morgan Stanley Smith Barney LLC.

How were the shares acquired for the TVTX Form 144 filing?

The shares were acquired on 09/22/2025 via a stock option exercise from the issuer, with payment in cash.

Does the filing show any prior sales by the same person in the past three months?

The filing states "Nothing to Report" under securities sold during the past three months.

Which broker is handling the proposed sale in the Form 144?

The broker named is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

What is the issuer's outstanding share count listed in the filing?

The filing lists 89,138,673 shares outstanding.
Travere Therapeutics Inc

NASDAQ:TVTX

TVTX Rankings

TVTX Latest News

TVTX Latest SEC Filings

TVTX Stock Data

3.20B
82.79M
0.75%
117.25%
13.55%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO